Delilah Alvarado is a staff reporter at BioPharma Dive. She covers a range of topics within medicine and healthcare, including diagnostics, biotech, and the healthcare system, while also drawing from her previous experience in business tech and startup news. Delilah's work has been featured in Yahoo Finance, Yahoo News, and Healthcare Dive.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Delilah Alvarado's coverage primarily focuses on the healthcare and pharmaceutical sectors, particularly on mergers and acquisitions, drug development, vaccines, and biotechnology. She regularly covers private sector announcements and press releases related to these themes.
Given her focus on mergers and acquisitions within the pharmaceutical industry, Delilah may be interested in pitches that offer insights into trends in M&A activity or exclusive information about upcoming deals. Additionally, she may be receptive to expert commentary from professionals with deep knowledge of the pharmaceutical industry.
As Delilah’s geographic focus is not specified but based on her coverage attributes she appears to cover international developments within the healthcare and pharmaceutical industries rather than focusing solely on a specific region.
This information evolves through artificial intelligence and human feedback. Improve this profile .
After an investigation, the agency concluded that a case of muscle weakness in one of Novavax’s trials was actually ALS and unrelated to vaccination.
By: Ned Pagliarulo, Delilah Alvarado
At an event hosted by BioPharma Dive, drugmaker executives and investors discussed the importance of focus, smart spending and maintaining lines of sight to the clinic.
Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain pediatric patients with an aggressive form of acute leukemia.
Executives at Applied Therapeutics told analysts they were surprised by the agency’s refusal to approve the company’s treatment for classic galactosemia.
Opens in a new window Opens an external website Opens an external website in a new window
By: Delilah Alvarado
Despite the disease’s prevalence, endometriosis remains misunderstood, and research into drugs that might treat it draws scant funding — problems that have deep roots.
By: Delilah Alvarado
“Sometimes the most under-hyped sectors are the best places to build very large businesses,” said one venture investor who attended Wednesday’s event.
After several severe RSV cases were reported in a pediatric trial of Moderna's vaccine, the FDA has partially paused testing in young children of certain shots for the virus.
By: Delilah Alvarado
An FDA approval of Merck’s drug clesrovimab by June would give physicians another option for protecting newborns from respiratory syncytial virus.
While the pharma is still developing a MorphoSys drug acquired in its $2.9 billion deal for the biotech, it is closing down sites in the U.S. and Germany.
(833) 317-6278 
